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esophageal squamous cell carcinoma (ESCC) patients 
including this group of tumors that had been excluded in the 
previous randomized studies. 
 
Material and Methods: A total of 202 patients who were 
diagnosed with stage II-III thoracic ESCC initiated NACRT 
between January 2003 and July 2014. Among them, 9 
patients refused further treatment during the course of 
NACRT and finally 200 patients were analyzed. For clinical 
staging, endoscopic ultrasonography was performed in 116 
(58.0%) and FDG PET/CT in all patients. 75 patients (37.5%) 
had supraclavicular or celiac LN metastasis, which staged as 
M1a (N=54, 27.0%) or M1b (N=21, 10.5%) according to the 6th 
edition of AJCC staging. 168 patients (84.0%) completed both 
NACRT and surgery, 79 (47.0%) of whom underwent 2 field LN 
dissection while 89 (53.0%) received 3 field LN dissection. 
Prognostic factors for survival were assessed using Cox 
regression. 
 
Results: After the median 17.8 months’ follow-up, patients 
(%) experienced disease progression and (%) died. In all 
patients, the 2-year locoregional control (LRC), disease free 
survival (DFS), and overall survival (OS) rates were %, 47.8%, 
and 67.9%, respectively. Following surgery, the pathologic 
complete response was achieved in 44 (26.2%) patients. In 
multivariate analysis, 3 field LN dissection (p=0.0439), ypT0 
(p=0.0380), ypN0 (p=0.0024), and negative surgical margin 
(p=0.0037) were favorable prognostic factors for DFS and 
negative surgical margin (p<0.0001) and age < 60 years 
(p=0.0411) were favorable factors for OS. The metastasis to 
supraclavicular and/or celiac LN was not significant factor for 
and DFS (p=0.5584) and OS (p=0.5874). 
 
Conclusion: Celiac and/or supraclavicular LN metastasis did 
not compromise treatment outcomes significantly following 
NACRT and surgery in selected patients who tolerates the 
trimodality treatment. 
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Purpose or Objective: Cancer of the gastroesophageal 
junction (GEJ) has been rising in incidence in recent years. 
The role of radiation therapy (RT) in the treatment of GEJ 
cancer remains unclear, as the largest prospective trials 
advocating for either adjuvant or neoadjuvant 
chemoradiotherapy (CRT) combine GEJ cancer with either 
gastric or esophageal cancer. The aim of the present study is 
to examine the effect of neoadjuvant versus adjuvant 
treatment on overall and disease-specific survival for 
patients with surgically resected cancer of the true GEJ 
(Siewert type II). 
 
Material and Methods: The Surveillance, Epidemiology, and 
End Results (SEER) registry database (2001-2011) was queried 
for cases of surgically resected Siewert type II 
gastroesophageal junction cancer. The variables obtained for 
each case include patient demographics (race/ethnicity, sex, 
age at presentation, year of diagnosis), disease 
characteristics (histologic grade, surgical stage/extent of 
disease, nodal status of the disease, presence of distant 
metastases), and treatment modalities (radiation sequence 
relative to surgery, type of surgery performed, and type of 
radiation administered). Patients with metastatic disease, no 
surgical intervention, and missing data were excluded from 
the cohort. 1497 patients with resectable GEJ cancer were 
identified, with 746 receiving adjuvant RT and 751 receiving 
neoadjuvant RT. Retrospective analysis was performed with 
the endpoints of overall and disease-specific survival. 
 
Results: Using cox regression and controlling for independent 
covariates (age, sex, race, stage, grade, histology, and year 
of diagnosis), we showed that adjuvant RT resulted in 
significantly lower death risk (hazard ratio [HR], 0.84; 95% 
confidence interval 0.73-0.97; p-value=0.0168) and 
significantly lower disease-specific death risk (HR, 0.84; 95% 
confidence interval, 0.72-0.97; p-value=0.0211) 
 
Conclusion: This analysis of SEER data showed a survival 
benefit for the use of adjuvant RT over neoadjuvant RT for 
the treatment of Siewert type II GEJ cancer. We suggest 
future prospective studies to compare outcomes of adjuvant 
versus neoadjuvant treatment for true GEJ cancer. 
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Purpose or Objective: We hypothesized that selected cases 
among patients with localized ALN recurrence in gastric 
cancer (GC) might be salvaged by integration of radiotherapy 
(RT) in the multimodal treatment. 
 
Material and Methods: We retrospectively identified patients 
with isolated ALN recurrence from GC between 2005 and 
2013. We categorized patients into two groups by treatment 
approach after diagnosis of ALN recurrence: those who 
treated with integration of RT to chemotherapy (RCT group) 
vs. those who received systemic chemotherapy only (CT 
group). 
 
Results: Of 53 patients with ALN recurrence from GC, 31 
patients were classified as RCT group and 22 as CT group. 
The isolated distant failure (DF; 11/31, 35.5%) was dominant 
pattern of failure (POF) in the RCT group (median DF-free, 26 
months). While local progression (LP) followed by DF (7/22, 
31.8%) was dominant POF in the CT group, in which LP 
(median LP-free, 8 months) occurred earlier than DF (median 
DF-free, 18 months). RCT group had significantly prolonged 
median PFS compared with CT group (25 vs. 8 months, p = 
0.021). In multivariate analysis, the treatment group was 
identified as independent prognostic factor related to PFS (p 
= 0.013). There was a borderline significance in OS between 
RCT group and CT group (29 vs. 20 months, p = 0.095). 
 
Conclusion: Integration of RT and chemotherapy influenced 
the pattern of failure, and significantly improved PFS with 
isolated ALN recurrence in recurrent GC. RT may be 
considered in the treatment course of isolated ALN 
recurrence. 
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Purpose or Objective: To review the treatment result of 
metachronous esophageal cancer (ESC) after head and neck 
cancer (HNC). 
 
